How I approach smoldering multiple myeloma
Authors:
Open Access
- 25 August 2022
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 140 (8) , 828-838
Abstract
The current standard of care in smoldering multiple myeloma (SMM) is close surveillance, outside of clinical trials. Efforts are being made to understand the pathobiologic process that leads to the progression of SMM to active MM. This review provides a critical description of available data, including risk factors and risk models of progression, as well as clinical trials investigating interventions for this patient population. We describe 2 cases in which patients were seen before the concept of a myeloma-defining event was established. Today, based on the International Myeloma Working Group criteria, both patients would have been identified as experiencing myeloma-defining events, and therapy would have been initiated. These cases show that occasionally, patients can undergo observation only, even when they exceed criteria for high-risk SMM.Keywords
This publication has 93 references indexed in Scilit:
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaLeukemia, 2013
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myelomaLeukemia, 2012
- High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myelomaLeukemia, 2012
- Diagnosis of Smoldering Multiple MyelomaNew England Journal of Medicine, 2011
- Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complicationsBlood, 2010
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008
- Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistryHuman Pathology, 2007
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaNew England Journal of Medicine, 2007
- Prognostic factors in low tumour mass asymptomatic multiple myeloma: A report on 91 patientsAmerican Journal of Hematology, 1995
- Smoldering Multiple MyelomaNew England Journal of Medicine, 1980